KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 11.49% to $48.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.2 million, a 11.49% increase, with the full-year FY2025 number at $48.2 million, up 11.49% from a year prior.
  • Total Non-Current Liabilities was $48.2 million for Q4 2025 at Xenon Pharmaceuticals, up from $45.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $48.2 million in Q4 2025 to a low of $43.2 million in Q4 2024.